Komatsu Tomoko, Yamazaki Hiroshi, Nakajima Miki, Yokoi Tsuyoshi
Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
Biochem Pharmacol. 2002 Jun 15;63(12):2081-90. doi: 10.1016/s0006-2952(02)01024-9.
We have reported previously that the formation of a 3',4'-dihydroxylated metabolite of phenytoin (3',4'-diHPPH) by human liver microsomal cytochrome P450 (P450) is enhanced by the addition of human liver cytosol [Komatsu et al., Drug Metab Dispos 2000;28:1361-8]. The enhancing factor was determined in this study. The addition of cytosolic proteins precipitated by 50% ammonium sulfate to incubation mixtures increased the rate of microsomal 3',4'-diHPPH formation. This fraction was separated further by diethylaminoethyl-, carboxymethyl-, and hydroxyapatite-column chromatography. The amino acid sequence of the purified protein of approximately 55kDa by electrophoresis revealed this protein to be a catalase. The addition of purified or authentic catalase to the incubation mixtures increased the rates of microsomal 3',4'-diHPPH formation from 3'- and 4'-hydroxylated metabolites and from phenytoin in a concentration-dependent manner. In reconstituted systems containing CYP2C9, CYP2C19, and CYP3A4, the formation of 3',4'-diHPPH was also enhanced by catalase to different extents. This is the first report that catalase in livers enhances drug oxidation activities catalyzed by P450 in human liver microsomes.
我们之前报道过,人肝微粒体细胞色素P450(P450)催化苯妥英形成3',4'-二羟基化代谢物(3',4'-二氢苯妥英,3',4'-diHPPH)的反应会因加入人肝细胞溶胶而增强[小松等人,《药物代谢与处置》2000年;28:1361 - 1368]。本研究确定了这种增强因子。向孵育混合物中加入经50%硫酸铵沉淀的胞质蛋白,可提高微粒体3',4'-diHPPH的形成速率。该组分通过二乙氨基乙基柱、羧甲基柱和羟基磷灰石柱色谱进一步分离。通过电泳纯化得到的约55kDa蛋白质的氨基酸序列显示该蛋白质为过氧化氢酶。向孵育混合物中加入纯化的或正宗的过氧化氢酶,可使微粒体从3'-和4'-羟基化代谢物以及苯妥英形成3',4'-diHPPH的速率呈浓度依赖性增加。在含有CYP2C9、CYP2C19和CYP3A4的重组系统中,过氧化氢酶也能不同程度地增强3',4'-diHPPH的形成。这是首次报道肝脏中的过氧化氢酶可增强人肝微粒体中P450催化的药物氧化活性。